

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T ~~Th~~ cells

wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

2. **(Cancelled)**

3. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out by transducing ~~a gene for~~ a class I-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-associated antigen.

4. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out by transducing ~~a gene for~~ a class II-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-associated antigen.

5. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 1, 3 or 4 ~~2 to 4~~, wherein the cancer-associated antigen is selected from the group

consisting of Wilms' Tumor 1 ~~WT1~~, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

6. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing helper T ~~Th~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.

7. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 1, 3, 4 or 6 ~~1 to 6~~, further comprising a step of purifying the helper T ~~Th~~ cells to which antigen specificity has been imparted.

8. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the helper T ~~Th~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

9. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T ~~1 Th1~~ cells and cytotoxic T ~~1 Te1~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells
wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is
carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

10. **(Cancelled)**

11. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells is carried out by transducing ~~a gene for a class I-restricted T cell receptor gene~~ TCR that recognizes a cancer-associated antigen.

12. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells is carried out by transducing ~~a gene for a class II-restricted T cell receptor gene~~ TCR that recognizes a cancer-associated antigen.

13. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9 to ~~12~~ 9, 11 or 12, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1 ~~WT1~~, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

14. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.

15. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14 ~~9 to 14~~, further comprising a step of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells to which antigen specificity has been imparted.

16. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

17. **(Currently Amended)** The process for preparing cells for cell therapy according to claim ~~15 or 16~~, further comprising a step of mixing the separated helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells in any given proportion.

18. **(Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T T_H cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

19. **(Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T 1 T_H1 cells and cytotoxic T 1 T_{E1} cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 T_H1 cells and cytotoxic T 1 T_{E1} cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

20. **(Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T T_H cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T T_H cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T T_H cells to which antigen specificity has been imparted.

21. **(Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Te1~~ cells to which antigen specificity has been imparted.